CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines

Immunology

Volumn 135, Issue 3, 2012, Pages 226-235

  Kim, Eun Ju ^a   Lee, Sang Min ^a   Suk, Kyoungho ^b   Lee, Won Ha ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

CD300a; Inflammation; Macrophage; Toll like receptor signalling

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN CD300A; PROTEIN CD300F; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; MONOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MOTIF; REPORTER GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANTIGENS, CD; CELL LINE; HUMANS; LIGANDS; MACROPHAGE ACTIVATION; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE FRAGMENTS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; U937 CELLS;

EID: 84862934143     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03528.x     Document Type: Article

References (42)

1. Cantoni C, Bottino C, Augugliaro R et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 1999; 29:3148-59.
2. Green BJ, Clark GJ, Hart DN. The CMRF-35 mAb recognizes a second leukocyte membrane molecule with a domain similar to the poly Ig receptor. Int Immunol 1998; 10:891-9.
3. + T lymphocyte subpopulations defined by CD300a/c molecule expression. J Leukoc Biol 2007; 82:1126-35.
4. Narayanan S, Silva R, Peruzzi G, Alvarez Y, Simhadri VR, Debell K, Coligan JE, Borrego F. Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin. PLoS ONE 2010; 5:e10636.
5. Alvarez Y, Tang X, Coligan JE, Borrego F. The CD300a (IRp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Mol Immunol 2008; 45:253-8.
6. Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 2006; 107:1996-2003.
7. Ju X, Zenke M, Hart DN, Clark GJ. CD300a/c regulate type I interferon and TNF-α secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 2008; 112:1184-94.
8. Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 2005; 175:7989-95.
9. Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol 2008; 180:6064-9.
10. Bachelet I, Munitz A, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 2006; 117:1314-20.
11. Bachelet I, Munitz A, Mankutad D, Levi-Schaffer F. Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): a novel interface in the allergic process. J Biol Chem 2006; 281:27190-6.
12. Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 2006; 118:1082-9.
13. Lee SM, Kim EJ, Suk K, Lee WH. CD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of SHP-1. J Immunol 2011; 186:6296-303.
14. Lee SM, Nam YP, Suk K, Lee WH. IREM-1 inhibits BAFF-mediated inflammatory regulation of THP-1 cells through modulation of the activities of ERK. Clin Exp Immunol 2010; 161:504-11.
15. Lee JK, Kim SY, Kim YS, Lee WH, Hwang DH, Lee JY. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem Pharmacol 2009; 77:1391-400.
16. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278:37041-51.
17. Kim JH, Jeong JH, Jeon ST et al. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-κB activation in macrophages. Mol Pharmacol 2006; 69:1783-90.
18. Jung DY, Lee H, Jung BY, Ock J, Lee MS, Lee WH, Suk K. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J Immunol 2005; 174:6467-76.
19. Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, Kwon BS, Park JE. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001; 21:2004-10.
20. Nasu K, Narahara H. Pattern recognition via the toll-like receptor system in the human female genital tract. Mediators Inflamm 2010; 2010:976024.
21. Alvarez-Errico D, Aguilar H, Kitzig F, Brckalo T, Sayos J, Lopez-Botet M. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur J Immunol 2004; 34:3690-701.
22. Sui L, Li N, Liu Q et al. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochem Biophys Res Commun 2004; 319:920-8.
23. Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol 2003; 171:6541-8.
24. Shibuya A, Nakahashi-Oda C, Tahara-Hanaoka S. Regulation of immune responses by the activating and inhibitory myeloid-associate immunoglobulin-like receptors (MAIR) (CD300). Immune Netw 2009; 9:41-5.
25. Izawa K, Kitaura J, Yamanishi Y et al. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. J Immunol 2009; 183:925-36.
26. Xi H, Katschke KJ Jr, Helmy KY et al. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med 2010; 207:7-16, S1-5.
27. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83.
28. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-κB proinflammatory responses. J Biol Chem 2009; 284:24192-203.
29. Zhang FX, Kirschning CJ, Mancinelli R et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274:7611-4.
30. Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10:1089-95.
31. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-κB activation. Nat Immunol 2004; 5:503-7.
32. Wietek C, Miggin SM, Jefferies CA, O'Neill LA. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-κ. J Biol Chem 2003; 278:50923-31.
33. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7.
34. Rowe DC, McGettrick AF, Latz E et al. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci U S A 2006; 103:6299-304.
35. Aksoy E, Vanden Berghe W, Detienne S, Amraoui Z, Fitzgerald KA, Haegeman G, Goldman M, Willems F. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-κB activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol 2005; 35:2200-9.
36. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169:6668-72.
37. Burns K, Martinon F, Esslinger C et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998; 273:12203-9.
38. Ishida T, Mizushima S, Azuma S et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996; 271:28745-8.
39. Lankry D, Simic H, Klieger Y, Levi-Schaffer F, Jonjic S, Mandelboim O. Expression and function of CD300 in NK cells. J Immunol 2010; 185:2877-86.
40. Lee SM, Kim EJ, Suk K, Lee WH. Stimulation of FasL induces production of pro-inflammatory mediators through activation of mitogen activated protein kinases and nuclear factor-κB in THP-1 cells. Inflammation 2011; in press.
41. Arabaci G, Guo XC, Beebe KD, Coggeshall KM, Pei D. α-Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J Am Chem Soc 1999; 121:5085-6.
42. Mannell H, Hellwig N, Gloe T et al. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res 2008; 45:153-63.